Maintenance therapy in CLL: resolving the controversy
Mené sur 263 patients atteints d'une leucémie lymphocytaire chronique ayant répondu à un traitement d'induction comprenant du rituximab, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du rituximab en traitement d'entretien (durée médiane de suivi : 34 mois)
The standard of care for chronic lymphocytic leukaemia is fast changing. For younger patients, frontline chemoimmunotherapy with regimens such as fludarabine, cyclophosphamide, and rituximab are still appropriate standard-of-care, whereas kinase inhibitors such as ibrutinib are commonly used in older patients, and in those with relapsed disease. Attempts to intensify the regimen of fludarabine, cyclophosphamide, and rituximab with addition of drugs such as mitoxantrone resulted in additional toxicity and no improvement in therapeutic efficacy.